Navigation Links
US FDA Grants Pediatric Exclusivity for UCB's Keppra(R)
Date:6/6/2008

43.1% of levetiracetam-treated patients experiencing at least a 50% reduction in seizure frequency during the evaluation period (five days) compared with 19.6% of placebo-treated patients (p=0.013). Levetiracetam was generally well-tolerated in this pediatric population. The most commonly reported adverse events that occurred more frequently in the treatment group were somnolence (13.3% vs. 1.8% for placebo) and irritability (11.7% vs. 0 for placebo). The incidence of other adverse events was similar in both groups.

In October 2007, UCB announced that it had reached an agreement to settle pending patent infringement lawsuits in the US. Under the terms of the settlement agreement with Mylan, and subject to its receiving FDA approval, Mylan will be allowed to sell its generic levetiracetam tablets effective November 1, 2008, in advance of the expiry of UCB's market exclusivity on January 14, 2009.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting 40 million people worldwide including 2.5 million people in the US. It is caused by abnormal, excessive electrical discharges of the nerve cells or neurons in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes and effective classification guides treatment and prognosis. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or significant adverse side effects secondary to medication highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the US: Keppra(R) (levetiracetam) tablets were first approved by the FDA in 1999 as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Since 1999, Keppra(R) has received several supplemental indications
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
2. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
3. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
4. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
5. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
6. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
7. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. United States Patent Office Grants CryoCors Request for Patent Interference
10. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... building materials using light, developed by researchers at the ... are often considered the realm of science fiction, such ... cloaked starships won,t be a reality for quite some ... materials with building blocks a few billionths of a ... that light flies through them, and works on large ...
(Date:7/28/2014)... , July 28, 2014 Sapphire ... technologies, today announced the appointment of biotechnology veteran ... the board of directors. Levine replaces Cynthia ,CJ, Warner, ... She will remain chairman of the company,s board of ... Sapphire Energy,s mission to deliver commercial scale algae-based fuels ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange ... of health IT to create efficiencies in healthcare information ... Workgroup has developed an issue brief titled, “What ... The HPID Workgroup, a part of WEDI’s Strategic National ... Medicare and Medicaid Services (CMS) to identify common misuse ...
(Date:7/28/2014)... “2014 Deep Research Report ... a professional and in-depth research report on ... introduces Lubricant basic information, including Lubricant definition, ... industry overview. This research covers the international ... well as global industry analysis covering macroeconomic ...
Breaking Biology Technology:Building 'invisible' materials with light 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4
... of Integrated Global Services, CAMBRIDGE, Mass., April ... under a new name, Abt Bio-Pharma Solutions, Inc., ... company will continue to,provide custom strategic, research and ... diagnostics industries,utilizing a team approach that blends decades ...
... 1, 2008 Cardium Therapeutics,(Amex: CXM ... announced today that,InnerCool has entered into a ... a leading distributor of cardiology,medical products. Under ... have,exclusive marketing, sales and distribution rights in ...
... N.J., April 1, 2008 Derma Sciences,Inc (OTC Bulletin ... that sales for 2007 were $34.1 million, an increase ... Gross margins held steady at 34,percent, but due primarily ... the,pipeline, and expanding the Company,s marketing and sales staffs, ...
Cached Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
(Date:7/28/2014)... About 100 drugs already approved by the U.S. Food ... prevent the growth of certain bacterial pathogens inside human ... Mediterranean spotted fever. The findings, published in mBio ... for Microbiology, demonstrate a new way of identifying non-antibiotic ... , A handful of drugs on the list ...
(Date:7/28/2014)... showing signs of damage from the Deepwater Horizon oil spill ... Gulf of Mexico. The discovery was made by a team ... University. A paper describing this work and additional impacts of ... be published during the last week of July 2014 in ... the National Academy of Sciences . , "The footprint of ...
(Date:7/28/2014)... the South Pole in 1911, but new research shows ... , Using data from 16 ice cores collected from ... South Pole, a group led by Joe McConnell of ... the most accurate and precise reconstruction to date of ... described in an article published today in the online ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... ,This multidisciplinary conference on "Fibrous Protein Nanocomposites for Tailored ... the art in the design, synthesis and characterization of ... applications. The conference will be held in the ... situated at the crossroads of the Mediterranean Sea, exposed ...
... Alejandro Heuck at the University of Massachusetts Amherst recently ... of Health to map the molecular structure of a ... in mammalian cell walls. Once a channel ... plague (Yersinia pestis), dysentery (Shigella), food poisoning (Salmonella) and ...
... - Scientists could take greater strides toward crop improvement ... to understand the mechanisms that allow plants to adapt ... say. In a perspective for the journal ... genetics, and Ivan Baxter, a research computational biologist for ...
Cached Biology News:Fibrous Protein Nanocomposites Conference 2Fibrous Protein Nanocomposites Conference 3UMass Amherst biochemists developing tools to stop plague and other bacterial threats 2UMass Amherst biochemists developing tools to stop plague and other bacterial threats 3Adoption of advanced techniques could propel crop improvement 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
... 100%,S-Adenosyl Methionine 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... Assay Range: 0.1 ug/ml to 1 mg/ml,(0.26 M to 2.6 mM) ...
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: